Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CRISPR THERAPEUTICS AG

(CRSP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.

Number of employees : 410 people.
Sales per Business
2020
Collaboration0.5475.5%
Grant0.1824.5%
USD in Million
Sales per region
20192020Delta
Switzerland and United States289.59100%0.72100% -99.75%
USD in Million
Managers
Name Title Age Since
Samarth Kulkarni Chief Executive Officer & Director 41 2018
Rodger Novak Chairman & President 52 2017
Brendan Smith Senior VP, Chief Financial & Accounting Officer 45 2021
Tony Ho Executive VP, Head-Research & Development 54 2017
Stephen Kennedy Head-Technical Operations 63 -
Lawrence Klein Chief Operating Officer 37 2020
Simeon J. George, Dr. Independent Non-Executive Director 43 2015
Ali Behbahani, Dr. Independent Non-Executive Director 44 2015
Bradley Bolzon Independent Non-Executive Director 60 2016
Katherine A. High, Dr. Independent Director 68 2019
Members of the board
Name Title Age Since
Rodger Novak Chairman & President 52 2017
Simeon J. George, Dr. Independent Non-Executive Director 43 2015
Ali Behbahani, Dr. Independent Non-Executive Director 44 2015
Bradley Bolzon Independent Non-Executive Director 60 2016
Samarth Kulkarni Chief Executive Officer & Director 41 2018
Katherine A. High, Dr. Independent Director 68 2019
John Greene Independent Director 54 2019
Douglas A. Treco, Dr. Independent Director 62 2020
Harold Edward Fleming Independent Director 57 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 76,707,280 66,706,152 87.0% 180,316 0.2% 87.0%
Shareholders
NameEquities%
ARK Investment Management LLC 7,585,674 9.95%
Capital Research & Management Co. (International Investors) 4,265,002 5.60%
Nikko Asset Management Americas, Inc. 3,289,516 4.32%
GlaxoSmithKline plc 3,220,627 4.23%
NEA Management Co. LLC 1,590,002 2.09%
Perceptive Advisors LLC 1,341,308 1.76%
T. Rowe Price Associates, Inc. (Investment Management) 1,184,729 1.55%
Ivy Investment Management Co. 1,071,487 1.41%
Macquarie Investment Management Business Trust 982,923 1.29%
Bellevue Asset Management AG 974,684 1.28%
Company contact information
CRISPR Therapeutics AG
Baarerstrasse 14
Zug 6300

Phone : +41.41.561.32.77
Web : http://www.crisprtx.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of CRISPR Therapeutics AG
Sector Other Biotechnology & Medical Research